证券代码：000756 证券简称：新华制药 公告编号：2024-19 山东新华制药股份有限公司 关于举办2023年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 山东新华制药股份有限公司（以下简称"公司"）已于 2024 年 3 月 29 日在巨潮资讯网 （www.cninfo.com.cn）上披露了《2023 年年度报告》及《2023 年年度报告摘要》。为便于 广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2024 年 4 月 28 日（星期天）15:00-16:00 在"价值在线"（www.ir-online.cn）举办公司 2023 年度网上业 绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 一、参会方式 本次年度业绩说明会将采用网络互动的方式举行，投资者可于 2024 年 4 月 28 日（星期 天）15:00-16:00 通过网址 https://eseb.cn/1dNnPuxloYM 或使用微信扫描下方小程序码即 可进入参与互动交流。 二、出席人员 出席本次网上业绩说明会的人员有：董事长 ...

证券代码：000756 证券简称：新华制药 公告编号：2024-18 山东新华制药股份有限公司 关于全资子公司头孢克洛胶囊通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 近日，山东新华制药股份有限公司（以下简称"本公司"）之全资子公司山东淄博新达 制药有限公司（以下简称"新达制药"）收到国家药品监督管理局核准签发的头孢克洛胶囊（以 下简称"本品"）《药品补充申请批准通知书》，该产品通过仿制药质量和疗效一致性评价， 现将相关情况公告如下： 一、基本情况 申请人：山东淄博新达制药有限公司 申请事项：仿制药质量和疗效一致性评价 受理号：CYHB2250649 原药品批准文号：国药准字H10930008 通知书编号：2024B01534 审批结论：通过仿制药质量和疗效一致性评价。 药品名称：头孢克洛胶囊 剂型：胶囊剂 规格：0.25g（按C15H14ClN3O4S计） 药品分类：处方药 注册分类：化学药品 新达制药的头孢克洛胶囊于2024年4月通过仿制药质量与疗效一致性评价，有利于进一 步提升该产品的市场竞争力。 因药品销售业务易受到国内医 ...

证券代码：000756 证券简称：新华制药 公告编号：2024-17 山东新华制药股份有限公司 关于取得帕拉米韦注射液药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药 品监督管理局核准签发的帕拉米韦注射液（15ml：0.15g）（以下简称"本品"） 《药品补充 申请批准通知书》，该产品上市许可持有人转让申请获得批准。现将相关情况公告如下： 一、基本情况 药品名称：帕拉米韦注射液 注册分类：化学药品 申请人：山东新华制药股份有限公司 申请事项：上市许可持有人变更申请 受理号：CYHB2400368 原药品批准文号：国药准字H20243128 通知书编号：2024B01462 审批结论：根据《中华人民共和国药品管理法》及相关规定，经审查，本品此次申请事 项符合药品注册的有关要求，同意按照《药品上市后变更管理办法（试行）》相关规定，批 准本品上市许可持有人由"苏州爱美津制药有限公司"变更为"山东新华制药股份有限公司"， 药品批准文号不变。 剂型：注射液 规格：1 ...

Financial Performance - The company reported a fully diluted earnings per share of RMB 0.7276 for the fiscal year 2023[14]. - The company's operating revenue for 2023 reached RMB 8,100,844,707.33, an increase of 7.97% compared to RMB 7,502,987,102.09 in 2022[33]. - The net profit attributable to shareholders of the listed company was RMB 496,512,201.25, reflecting a growth of 20.79% from RMB 411,063,056.58 in the previous year[33]. - The net cash flow from operating activities decreased significantly by 65.01% to RMB 265,278,895.87, down from RMB 758,240,601.50 in 2022[33]. - The total assets as of the end of 2023 were RMB 8,286,166,330.90, a slight increase of 0.26% from RMB 8,264,790,395.98 at the end of 2022[33]. - The total liabilities decreased by 10.34% to RMB 3,510,413,044.14, compared to RMB 3,915,226,169.32 in the previous year[33]. - The basic earnings per share increased by 19.35% to RMB 0.74, up from RMB 0.62 in 2022[33]. - The weighted average return on net assets rose to 11.41%, an increase of 0.80 percentage points from 10.61% in the previous year[33]. - The total comprehensive income for the year amounted to RMB 411,063,056.58, reflecting a significant increase compared to the previous year[152]. - The company reported a net loss of RMB 132,207,856.16 for the year, impacting overall financial performance[152]. Shareholder Information - The board proposed a final dividend of RMB 0.25 per share for the year ending 2023, based on a total share capital of 682,407,635 shares[9]. - As of December 31, 2023, the total number of shareholders was 97,594, including 39 H-share shareholders and 97,555 A-share shareholders[17]. - The largest shareholder, Hualu Holdings, held 204,864,092 shares, representing a significant portion of the company's equity[19]. - The largest shareholder, China Hualu Holdings Group Co., Ltd., holds 30.36% of the shares, totaling 204,864,092 shares[38]. - Hong Kong Central Clearing (Agent) Co., Ltd. holds 28.65% of the shares, totaling 193,314,147 shares, with an increase of 11,220 shares during the reporting period[38]. - Hualu Investment Development Co., Ltd., a wholly-owned subsidiary of China Hualu Holdings, holds 5.50% of the shares, totaling 37,091,988 shares[38]. - The top ten shareholders do not have any pledged or frozen shares, nor do they participate in securities lending[39]. - The report indicates that there are no known relationships among the other shareholders or any concerted actions as per the regulations[40]. - The company has a total of 10 major shareholders, with the top four holding over 64% of the total shares[38]. - The report does not disclose any significant changes in the shareholding structure of the board members and senior management as of December 31, 2023[52]. Corporate Governance - The company’s ultimate controller remains the State-owned Assets Supervision and Administration Commission of Shandong Province[22]. - The company’s governance structure is in compliance with relevant regulations for listed companies in China[91]. - The company’s board of directors held a total of 7 meetings in the year, with independent directors actively participating[77]. - The company held 5 meetings of the Board of Directors' Audit Committee in 2023, with independent directors attending all meetings without any absences[92]. - The Audit Committee confirmed that the financial statements for the year 2023 were prepared in accordance with the accounting policies and standards, and no significant misstatements were found[94]. - The company’s board of directors and supervisors will serve until December 22, 2026[67]. - The company has undergone changes in its board members, with new elections held on December 22, 2023[70]. - The independent director, Lu Huawai, resigned on December 22, 2023, after attending 6 out of 7 board meetings in the year[77]. Employee Information - As of December 31, 2023, the group employed a total of 7,104 employees, with a total salary expenditure of RMB 743.778 million[71]. - The employee distribution by function includes 3,922 production personnel, 895 sales personnel, and 656 engineering technical personnel[72]. - The educational background of employees shows that 1,870 hold a university degree or above, while 2,323 have a college diploma[73]. - The total annual remuneration for directors, supervisors, and senior management in 2023 amounted to RMB 12.5571 million[70]. - The total remuneration for directors in 2023 amounted to 1,215,250, an increase from 720,250 in 2022, representing a growth of approximately 68.8%[79]. - The chairman, He Tongqing, received a remuneration of 183,150 in 2023, up from 110,550 in 2022, reflecting a 65.5% increase[79]. - The financial officer, Hou Ning, received a remuneration of 220,000 in 2023, compared to 147,400 in 2022, marking a 49.2% increase[79]. - The company has conducted 71 training projects in 2023, training a total of 3,365 participants, enhancing employee skills and management effectiveness[89]. - The company has a structured education and training system aimed at improving employee capabilities and ensuring effective management operations[89]. Operational Focus and Market Presence - The company has been actively expanding its market presence and product offerings in the pharmaceutical sector[8]. - The company’s major operational focus includes investments in the chemical, pharmaceutical, and environmental protection industries[54]. - The company has established long-term strategic partnerships with over 200 multinational corporations, including Bayer and GlaxoSmithKline, enhancing its international market presence[136]. - The company is recognized as one of the top five pharmaceutical exporters in China and is actively pursuing internationalization strategies[136]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[152]. Environmental and Social Responsibility - The company invested RMB 225.43 million in environmental protection in 2023 and paid RMB 143,000 in environmental protection tax[100]. - The company established an environmental management system in 1999 and has passed multiple certifications, including the latest in 2023[100]. - The company provided financial assistance totaling RMB 521,215.80 to 334 employees in need during 2023[103]. - The company has been recognized as an excellent talent training base in the Shandong pharmaceutical industry and a demonstration base for corporate training in China[102]. Research and Development - The company has established a comprehensive new drug research and development system, with over 100 products currently under research[137]. - The company has developed seven major series of raw materials, including Ibuprofen and Aspirin, and has made significant technological advancements in new products[136]. - The company has established six research and development platforms, focusing on innovative drug delivery systems and precision medicine[137]. - The company holds a 50.1% equity stake in Zibo Xinhua-Baili Pharmaceutical Co., Ltd., which reported total assets of RMB 315,846 thousand and net profit of RMB 12,080 thousand for the year, with a revenue decline of 17.61% year-over-year[121]. - The company also owns 60% of Shandong Tongxin Pharmaceutical Co., Ltd., which achieved revenue of RMB 4,526 thousand and net profit of RMB 322 thousand in 2023[134]. - The company has 21 active pharmaceutical ingredients registered with the US FDA and 12 products certified by the EU CEP[137]. Financial Management and Reporting - The company has made adjustments to previous financial statements, but these adjustments did not have a significant impact on operations[33]. - The company has maintained effective internal controls in all significant aspects throughout the year[106]. - The company has not engaged in any investment management activities during the reporting period[108]. - The company's cash and cash equivalents decreased from RMB 864.20 million at the beginning of the year to RMB 619.96 million at the end of the year[145]. - The company's total assets amounted to RMB 6.90 billion, a slight decrease from RMB 6.99 billion at the beginning of the year[145]. - The company's inventory increased from RMB 755.13 million to RMB 809.70 million during the reporting period[145]. - The group’s asset-liability ratio stood at 42.36%, calculated as total liabilities divided by total assets multiplied by 100%[118]. - The total capital debt ratio was 29.81%, and the net capital debt ratio was 9.64% as of December 31, 2023[119]. - The expected credit loss rates for accounts receivable are set at 0.50-1.00% for within 1 year, 20.00-50.00% for 1-2 years, 60.00-100.00% for 2-3 years, and 100.00% for over 3 years[177]. - The company applies a three-stage model for expected credit loss measurement, assessing credit risk at each balance sheet date[178]. - The company recognizes financial guarantees at the lower of the carrying amount of the financial asset and the guarantee amount received[180]. - The company’s financial statements are prepared following the principle of materiality, with significant judgments made regarding the importance of disclosed matters[189]. - The company’s operating cycle is defined as 12 months, which is used as a standard for classifying assets and liabilities[188]. - The company measures financial assets at fair value upon initial recognition, with certain receivables measured at transaction price[197]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired in a business combination[190]. - The company assesses whether there has been a significant increase in credit risk since initial recognition to determine the appropriate stage for expected credit loss[178]. - The company’s inventory is valued at the lower of cost and net realizable value, with provisions made for inventory write-downs when necessary[183].

山东新华制药股份有限公司 独立董事 2023 年度述职报告 本人，潘广成，作为山东新华制药股份有限公司（"公司"）的独立董事，2023 年度 严格按照《公司法》、《证券法》、《上市公司治理准则》、《上市公司独立董事管理办法》 等有关法律、法规的规定及《公司章程》的要求，认真履行各项职责，促进公司规范运作， 促进公司治理不断完善，对相关事项发表了独立客观的意见，充分发挥独立董事的独立作用， 维护公司的整体利益，维护全体股东尤其是中小股东的合法权益。现将 2023 年度履行独立 董事职责情况报告如下： 一、独立董事的基本情况 公司于 2023 年 12 月 22 日召开股东大会进行了换届选举，本人被选举连任公司第十一 届董事会独立董事，本人的基本情况请详见公司《2023 年年度报告》中披露的简历。另外 本人还担任公司董事会下属的提名委员会主席、战略发展委员会委员、独立独立审核委员会 委员、薪酬与考核委员会委员。 作为公司的独立董事，本人具备履行职责所必需的专业知识和相关经验，并且与公司不 存在关联关系及相关利益安排，故不存在任何影响独立性的情况。 二、2023 年度履职概况 （一）出席会议情况 报告期内，董事会共 ...

山东新华制药股份有限公司董事会审核委员会 对会计师事务所 2023 年度履职情况评估及履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》《国 有企业、上市公司选聘会计师事务所管理办法》和《深圳证券交易所上市公司自律监管指引 第 1 号——主板上市公司规范运作》等规定和要求，董事会审核委员会本着勤勉尽责的原 则，恪尽职守，认真履职。现将董事会审核委员会对会计师事务所 2023 年度履职情况评估 及履行监督职责情况汇报如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 名称：信永中和会计师事务所（特殊普通合伙）（"信永中和"） 成立日期：2012 年 3 月 2 日（京财会许可【2011】0056 号） 组织形式：特殊普通合伙企业 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 按照《审计业务约定书》，遵循《中国注册会计师审计准则》和其他执业规范，信永中 和对公司2023年度财务报告及2023年12月31日的财务报告内部控制的有效性进行了审计， 同时对公司控股股东及其他关联方占用资金情况等进行核查并出具了专项报告。 经审计 ...

经核查独立董事潘广成先生、朱建伟先生、凌沛学先生、张菁菁女士的任职经 历以及签署的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系 或其他可能妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上市公司 独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 1 号--主板上市 公司规范运作》中对独立董事独立性的相关要求。 山东新华制药股份有限公司董事会 山东新华制药股份有限公司董事会 关于对独立董事独立性评估的专项意见 根据证监会《上市公司独立董事管理办法》、深圳证券交易所《股票上市规则》 《深圳证券交易所上市公司自律监管指引第 1 号--主板上市公司规范运作》等要求， 山东新华制药股份有限公司（以下简称"公司"）董事会，就公司在任独立董事潘 广成先生、朱建伟先生、凌沛学先生、张菁菁女士的独立性情况进行评估并出具如 下专项意见： 2024 年 3 月 28 日 ...

5 名监事赞成本议案，0 票反对，0 票弃权。 二、通过二零二三年度报告及业绩公告，并同意董事会将其提交二零二三年度周年股东 大会审议。 山东新华制药股份有限公司 会议审议并通过了以下议案： 一、通过二零二三年度监事会报告，并将提交二零二三年度周年股东大会审议。 二零二三年度监事会报告见同日发布于巨潮资讯网（http://www.cninfo.com.cn）的《山 东新华制药股份有限公司二零二三年年度报告》第十一节。 证券代码：000756 证券简称：新华制药 公告编号：2024-13 第十一届监事会第二次会议决议公告 本公司全体监事保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 山东新华制药股份有限公司（"本公司"）第十一届监事会第二次会议通知于二零二四 年三月十四日以电邮形式发出，会议于二零二四年三月二十八日在山东省淄博市高新区鲁泰 大道 1 号公司会议室召开，应到会监事 5 名，实际到会监事 5 名。会议的召开符合有关法律、 法规、规章和公司章程的规定。会议由本公司监事会主席刘承通主持。 根据《企业会计准则解释第 16 号》"关于单项交易产生的资产和负债相关的递延所得 税不适 ...

2023 年 7 月 26 日，本人因需投入更多时间处理其他事务，辞任公司独立董事。公司于 2023 年 12 月 22 日召开股东大会进行了换届选举，本人被重新选举为公司第十一届董事会 独立董事，本人的基本情况请详见公司《2023 年年度报告》中披露的简历。另外本人还担 任公司董事会下属的战略发展委员会委员、独立审核委员会委员、薪酬与考核委员会委员。 作为公司的独立董事，本人具备履行职责所必需的专业知识和相关经验，并且与公司不 存在关联关系及相关利益安排，故不存在任何影响独立性的情况。 二、2023 年度履职概况 山东新华制药股份有限公司 独立董事 2023 年度述职报告 本人，凌沛学，作为山东新华制药股份有限公司（"公司"）的独立董事，2023 年度 严格按照《公司法》、《证券法》、《上市公司治理准则》、《上市公司独立董事管理办法》 等有关法律、法规的规定及《公司章程》的要求，认真履行各项职责，促进公司规范运作， 促进公司治理不断完善，对相关事项发表了独立客观的意见，充分发挥独立董事的独立作用， 维护公司的整体利益，维护全体股东尤其是中小股东的合法权益。现将 2023 年度履行独立 董事职责情况报告如下： ...

中泰证券股份有限公司关于山东新华制药股份有限公司 2023 年度持续督导保荐工作报告 | 保荐机构名称：中泰证券股份有限公司 | 被保荐公司简称：新华制药 | | --- | --- | | 保荐代表人姓名：白仲发 | 联系电话：0531-68889218 | | 保荐代表人姓名：王静 | 联系电话：0531-68889839 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于 | | | 防止关联方占用公司资源的制度、募集资金管理制 | 是 | | 度、内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 不适用 | | （2）公司募集资金项目进展是否与信息披露文件一 | 不适用 | | 致 | | | 4、公 ...